3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma
用于视网膜母细胞瘤研究的 3 维视网膜类器官平台
基本信息
- 批准号:10263901
- 负责人:
- 金额:$ 49.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAffectAnimal ModelAnimalsBar CodesBiocompatible MaterialsBiologicalBiological ModelsBiomimeticsBioreactorsCRISPR/Cas technologyCellsChildClinical ManagementClone CellsCulture TechniquesCustomDNA sequencingDataDefectDependenceDeveloped CountriesDeveloping CountriesDevelopmentDiseaseDrug TargetingEmbryoEngineeringEnvironmentEquilibriumEventExcisionEyeGenesGeneticGenetic TranscriptionGenetically Engineered MouseHealthHumanHypoxiaInvadedKnowledgeLaboratoriesLeadLeftLifeLightMalignant - descriptorMalignant Childhood NeoplasmMalignant NeoplasmsModelingMolecularMolecular AbnormalityMusMutationNatureNeoplasm MetastasisNeural RetinaNormal tissue morphologyNuclear Orphan ReceptorOptic NerveOrganOrganoidsOutputOxygenParentsPathway interactionsPatientsPatternPharmacologyPhasePhenotypePhotoreceptorsPhysiologicalProceduresProliferatingRB1 geneResolutionRetinaRetinal ConeRetinal NeoplasmsRetinal PhotoreceptorsRetinoblastomaRodSavingsSeedsStimulusSurvival RateSystemTP53 geneTechnologyTestingTherapeuticTimeTissue EngineeringTissuesTumor Suppressor ProteinsUndifferentiatedVisionVisualVisual impairmentbasebioinformatics pipelinecancer genomicscell typechildhood cancer mortalityclinical phenotypecostdesigndifferentiation protocoldrug developmentdruggable targetestrogen-related receptorgenetic analysisgenetic corepressorgenetic manipulationgenomic aberrationshuman diseaseimprovedin silicoin uteroinduced pluripotent stem cellmalignant neoplasm of eyemouse modelmultidisciplinarymutantneoplastic cellnew technologynext generationp107 proteinpremalignantpreservationpsychologicretinal neuronretinal progenitor cellretinogenesissingle-cell RNA sequencingsocial stigmastem cell biologytargeted treatmenttherapeutic candidatetissue culturetranscriptome sequencingtumortumor progression
项目摘要
Project Summary/Abstract
Retinoblastoma (Rb) is the most common eye cancer in children and a significant contributor to childhood cancer
deaths worldwide. Rb tumors arise from biallelic loss of the RB1 gene during retinal development in-utero, and
are uniformly lethal if left untreated. While clinical management of the tumor has advanced in recent decades,
the non-specific and highly toxic nature of current therapies frequently result in life-long visual compromise and
health complications. Similarly, the exorbitant cost and limited access to advanced procedures render the best
treatment options inaccessible to most children worldwide, where eye removal remains the only life-saving option
for patients. However, the social stigma and psychological effects of eye removal often lead parents to forego
treatment, resulting in survival rates below 50% in many regions of the world. The most significant barrier to
progress in developing targeted selective therapies for retinoblastoma is the gap in knowledge regarding the
molecular drivers of retinoblastoma progression. Currently, no laboratory models exist, animal or otherwise,
which faithfully recapitulate the human manifestation of this disease, and the limited amount of information
available comes from tumors which necessitate removal, thus only providing a snapshot of the molecular
mechanisms present in advanced cases. The ability to study these tumors in earlier stages, including their pre-
malignant phase would shed light into the molecular drivers of Rb progression, lead to more targeted therapies
which obviate the need for eye removal, ideally preserving vision but, more importantly, save lives. Recently, we
have developed a human iPSC-based 3-Dimensional retinal organoid differentiation protocol and tissue culture
bioreactor system in which we can control various environmental parameters critical for proper retinal
development. Using this platform, we can use gene editing to introduce the most prevalent mutations found in
Rb tumors and evaluate their effect on retinal development and tumor formation. We have shown how some of
these mutations lead to amplification of a pre-malignant undifferentiated mutant cell clone, and disrupt terminal
differentiation of other retinal cell types. We now propose to establish this platform as the first model system in
which the various aspects of human Rb tumors can be elucidated, from their initiation through the drivers of
malignant transformation. In order to achieve this, we aim to 1) Optimize, validate, and deploy our tissue
bioreactor system to recapitulate the microenvironment of the developing retina, 2) use gene editing technology
to establish the physiologic pattern of mutation acquisition during retinogenesis which leads to Rb tumor
formation, and 3) use our 3D retinal organoid platform to screen pharmacological compounds that can address
the molecular determinants of Rb tumor progression.
项目总结/摘要
视网膜母细胞瘤(Rb)是儿童最常见的眼癌,也是儿童癌症的重要贡献者
全球死亡。Rb肿瘤是由于视网膜在子宫内发育过程中RB 1基因的双等位基因缺失引起的,
如果不治疗的话都是致命的虽然近几十年来肿瘤的临床治疗取得了进展,
目前治疗非特异性和高毒性的性质经常导致终身视力损害,
健康并发症。同样,高昂的费用和获得先进程序的机会有限,
全球大多数儿童无法获得治疗选择,摘除眼睛仍然是唯一挽救生命的选择
对患者然而,摘除眼睛的社会耻辱和心理影响往往导致父母放弃
在世界许多地区,存活率低于50%。最大的障碍是
视网膜母细胞瘤的靶向选择性治疗的进展是关于视网膜母细胞瘤的知识的差距。
视网膜母细胞瘤进展的分子驱动因素。目前,没有实验室模型存在,动物或其他,
它忠实地概括了这种疾病的人类表现,以及有限的信息量,
可用的来自需要切除的肿瘤,因此仅提供了分子水平的快照。
在先进的情况下存在的机制。在早期阶段研究这些肿瘤的能力,包括它们的前
恶性阶段将揭示Rb进展的分子驱动因素,导致更多的靶向治疗
这消除了摘除眼睛的需要,理想地保留了视力,但更重要的是,可以挽救生命。最近我们
已经开发了基于人iPSC的三维视网膜类器官分化方案和组织培养
生物反应器系统,我们可以控制各种环境参数的关键适当的视网膜
发展使用这个平台,我们可以使用基因编辑来引入在基因组中发现的最常见的突变。
Rb肿瘤,并评估其对视网膜发育和肿瘤形成的影响。我们已经展示了一些
这些突变导致癌前未分化突变细胞克隆的扩增,并破坏终末
其他视网膜细胞类型的分化。我们现在建议建立这个平台,作为
其中人类Rb肿瘤的各个方面可以阐明,从它们的开始通过驱动程序,
恶性转化为了实现这一目标,我们的目标是:1)优化、验证和部署我们的组织
生物反应器系统来重现发育中的视网膜的微环境,2)使用基因编辑技术
建立视网膜发生过程中突变获得的生理模式,从而导致Rb肿瘤
形成,以及3)使用我们的3D视网膜类器官平台来筛选可以解决
Rb肿瘤进展的分子决定因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES WILLIAM HARBOUR其他文献
JAMES WILLIAM HARBOUR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES WILLIAM HARBOUR', 18)}}的其他基金
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
葡萄膜黑色素瘤肝转移表观遗传状态的表征和靶向
- 批准号:
10298599 - 财政年份:2021
- 资助金额:
$ 49.28万 - 项目类别:
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
葡萄膜黑色素瘤肝转移表观遗传状态的表征和靶向
- 批准号:
10675515 - 财政年份:2021
- 资助金额:
$ 49.28万 - 项目类别:
Diversity Supplement for Molecular Predictive Testing in Ocular Melanoma
眼部黑色素瘤分子预测测试的多样性补充
- 批准号:
10220448 - 财政年份:2020
- 资助金额:
$ 49.28万 - 项目类别:
3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma
用于视网膜母细胞瘤研究的 3 维视网膜类器官平台
- 批准号:
10447198 - 财政年份:2020
- 资助金额:
$ 49.28万 - 项目类别:
3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma
用于视网膜母细胞瘤研究的 3 维视网膜类器官平台
- 批准号:
10657628 - 财政年份:2020
- 资助金额:
$ 49.28万 - 项目类别:
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMA
眼部黑色素瘤的分子预测测试
- 批准号:
7953938 - 财政年份:2009
- 资助金额:
$ 49.28万 - 项目类别:
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMA
眼部黑色素瘤的分子预测测试
- 批准号:
7721521 - 财政年份:2008
- 资助金额:
$ 49.28万 - 项目类别:
Molecular Predictive Testing in Ocular Melanoma
眼部黑色素瘤的分子预测测试
- 批准号:
7250878 - 财政年份:2006
- 资助金额:
$ 49.28万 - 项目类别:
Molecular Predictive Testing in Ocular Melanoma
眼部黑色素瘤的分子预测测试
- 批准号:
9902342 - 财政年份:2006
- 资助金额:
$ 49.28万 - 项目类别:
Molecular Predictive Testing in Ocular Melanoma
眼部黑色素瘤的分子预测测试
- 批准号:
7467990 - 财政年份:2006
- 资助金额:
$ 49.28万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 49.28万 - 项目类别:
Research Grant